ORIC Pharmaceuticals, Inc.
ORIC
$5.26
-$0.52-9.00%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 28.82M | 28.17M | 27.35M | 26.48M | 25.61M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 142.90M | 134.75M | 125.12M | 114.09M | 110.78M |
Operating Income | -142.90M | -134.75M | -125.12M | -114.09M | -110.78M |
Income Before Tax | -127.85M | -119.87M | -110.78M | -101.76M | -100.70M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -127.85 | -119.87 | -110.78 | -101.76 | -100.70 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -127.85M | -119.87M | -110.78M | -101.76M | -100.70M |
EBIT | -142.90M | -134.75M | -125.12M | -114.09M | -110.78M |
EBITDA | -141.79M | -133.69M | -124.06M | -113.05M | -109.75M |
EPS Basic | -1.83 | -1.81 | -1.76 | -1.81 | -1.97 |
Normalized Basic EPS | -1.14 | -1.13 | -1.10 | -1.13 | -1.23 |
EPS Diluted | -1.83 | -1.81 | -1.76 | -1.81 | -1.97 |
Normalized Diluted EPS | -1.14 | -1.13 | -1.10 | -1.13 | -1.23 |
Average Basic Shares Outstanding | 278.89M | 265.70M | 252.56M | 227.87M | 205.61M |
Average Diluted Shares Outstanding | 278.89M | 265.70M | 252.56M | 227.87M | 205.61M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |